World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Trial StartEntolimodPositive

AI Analysis

Summary

Sheba Medical Center has selected Valion Bio's Entolimod for clinical evaluation in cancer patients, establishing a second development pathway beyond Acute Radiation Syndrome into the neutropenia market.

Clinical Trial Data

Importance:6/10

Sentiment:

0.70

Clinical TrialNeutropeniaOncologyPartnershipAcute Radiation Syndrome

Related Companies

$MDCE $WHEN

Read the original article

Published by PR Newswire Biotech on July 20, 2026 5:28 PM

Read Original